Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer

FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer

Apr 17, 2019
|
staff reporter

NEW YORK (360Dx) – Agilent Technologies announced on Tuesday that the US Food and Drug Administration has expanded its approval of the firm's Dako PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic test for Merck's anti-PD1 immunotherapy pembrolizumab (Keytruda) for non-small cell lung cancer (NSCLC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

  2. Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

  3. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

  4. PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

  5. Snibe Diagnostic Obtains CE Mark for HIV Chemiluminescence Immunoassay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.